Support By : Li-lab
| PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
|---|---|---|---|---|---|
| Jak-STAT signaling pathway | R-HSA-168638 | map04630 | methotrexate | 126941 | drug-path |
| Regulation of actin cytoskeleton | R-HSA-392751 | map04810 | methotrexate | 126941 | drug-path |
| Hematopoietic cell lineage | R-HSA-173752 | map04640 | methotrexate | 126941 | drug-path |
| Adherens junction | R-HSA-451386 | map04520 | methotrexate | 126941 | drug-path |
| Cell adhesion molecules (CAMs) | R-HSA-1031690 | 0 | methotrexate | 126941 | drug-path |
| Cell cycle | R-HSA-1640170 | map04110 | methotrexate | 126941 | drug-path |
| Parkinson's disease | R-HSA-1643685 | 0 | methotrexate | 126941 | drug-path |
| Cytokine-cytokine receptor interaction | R-HSA-6788467 | map04060 | methotrexate | 126941 | drug-path |
| Graft-versus-host disease | R-HSA-1643685 | map05332 | mifepristone | 55245 | drug-path |
| Autoimmune thyroid disease | R-HSA-1643685 | map05320 | mifepristone | 55245 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | mifepristone | 55245 | drug-path |
| Allograft rejection | R-HSA-9679028 | map05330 | mifepristone | 55245 | drug-path |
| Type I diabetes mellitus | R-HSA-5683209 | map04940 | mifepristone | 55245 | drug-path |
| Natural killer cell mediated cytotoxicity | R-HSA-5218921 | map04650 | mifepristone | 55245 | drug-path |
| Hematopoietic cell lineage | R-HSA-173752 | map04640 | mifepristone | 55245 | drug-path |
| Alzheimer's disease | R-HSA-1643685 | 0 | mifepristone | 55245 | drug-path |
| Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | mifepristone | 55245 | drug-path |
| Huntington's disease | R-HSA-1643685 | 0 | mifepristone | 55245 | drug-path |
| Cell adhesion molecules (CAMs) | R-HSA-1031690 | 0 | mifepristone | 55245 | drug-path |
| Focal adhesion | R-HSA-354113 | map04510 | mifepristone | 55245 | drug-path |